HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stumpf, J. L. Search for Related Content PubMed PubMed Citation Articles by Stumpf, J. L.

JANICE L. STUMPF, PHARM.D., is Clinical Pharmacist, Drug Information Service and Clinical Associate Professor, University of Michigan Health System and College of Pharmacy, Ann Arbor.

Address correspondence to Mary Ellen Bonk, Pharm.D., University HealthSystem Consortium, 2001 Spring Road, Suite 700, Oak Brook, IL 60523-1890 (bonk{at}uhc.edu).

Purpose. The pharmacology, clinical efficacy, adverse effects and toxicities, and the economic issues that should be considered in using deferasirox are reviewed. Summary. Iron overload is a complication of the chronic blood transfusions used to treat several hematologic disorders. To date, management of transfusional iron overload has consisted of chelation therapy with parenteral deferoxamine. Although survival rates improve with adequate chelation, an estimated one third to one half of patients are not compliant with deferoxamine therapy, largely because of the discomfort and demanding nature of the regimen. In 2005, the Food and Drug Administration approved the labeling for deferasirox for the treatment of chronic overload due to transfusional hemosiderosis. Deferasirox is an oral tridentate chelator that mobilizes iron stores by binding selectively to the ferric form of iron. Deferasirox has been studied in >700 adult and pediatric patients who had transfusion-related iron overload and underlying thalassemia, sickle cell anemia, myelodysplastic syndrome, Diamond–Blackfan syndrome, or another rare anemia. The largest clinical study to date demonstrated the noninferiority of deferasirox 20 or 30 mg/kg/day compared with subcutaneous infusions of deferoxamine 35 mg/kg/day administered five days weekly in a subgroup of patients with higher hepatic iron burdens. Deferasirox has been well tolerated in clinical trials. Nearly 97% of participants in a comparative study stated that they preferred deferasirox over their previous deferoxamine treatment. Conclusion. Deferasirox, a tridentate oral chelator approved for the treatment of chronic iron overload due to blood transfusions, offers a promising alternative for patients unwilling or unable to comply with deferoxamine therapy. Index terms: Blood; Compliance; Costs; Deferasirox; Deferoxamine; Dosage; Drug comparisons; Heavy metal antagonists; Iron; Mechanism of action; Metals; Patients; Pediatrics; Pharmacoeconomics; Poisoning; Toxicity

 

This article has been cited by other articles:

				G. Brosnahan, N. Gokden, and S. Swaminathan Acute interstitial nephritis due to deferasirox: a case report Nephrol. Dial. Transplant., July 24, 2008; (2008) gfn423v1. [Abstract] [Full Text] [PDF]